
    
      The purpose of this study is to explore diazoxide efficacy in treatment of obese men and
      assessment of maximal insulin suppression in obese men without hyperglycaemia.

      Study design:

      This study is an open-labelled, non-randomized, phase IIa study.

      Treatment:

      During a 6 month period, the dosage of Diazoxide will be raised gradually until a maximum of
      900 mg/day, under control of bloodpressure and glucose levels.

      Endpoints, monthly determined:

        -  body weight

        -  abdominal circumference

        -  body composition measured by Dual Energy X-ray Absorptiometry

        -  glucose tolerance
    
  